Bruker Co. (NASDAQ:BRKR)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $35.51 and last traded at $35.37, with a volume of 159900 shares traded. The stock had previously closed at $35.22.
A number of brokerages have commented on BRKR. Cowen restated a “hold” rating and issued a $29.00 target price on shares of Bruker in a research note on Friday, November 3rd. Zacks Investment Research downgraded shares of Bruker from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Bank of America upgraded shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a research note on Friday, November 3rd. Finally, Goldman Sachs Group restated a “sell” rating and issued a $24.00 target price on shares of Bruker in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $29.64.
The company has a market cap of $5,502.25, a P/E ratio of 30.23, a price-to-earnings-growth ratio of 2.99 and a beta of 1.05. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. Bruker’s revenue was up 10.6% compared to the same quarter last year. During the same period last year, the firm earned $0.32 earnings per share. sell-side analysts anticipate that Bruker Co. will post 1.19 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be paid a $0.04 dividend. The ex-dividend date is Friday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.44%. Bruker’s dividend payout ratio (DPR) is 17.02%.
In other Bruker news, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the transaction, the vice president now owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The transaction was disclosed in a filing with the SEC, which is available at this link. 35.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Bruker by 3.0% in the second quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after buying an additional 139,792 shares during the last quarter. Boston Partners raised its holdings in shares of Bruker by 3.6% during the second quarter. Boston Partners now owns 2,773,019 shares of the medical research company’s stock worth $79,973,000 after purchasing an additional 96,791 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Bruker by 6.8% during the second quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after purchasing an additional 123,322 shares during the last quarter. AJO LP purchased a new position in shares of Bruker during the second quarter worth $46,075,000. Finally, Marshall Wace North America L.P. raised its holdings in shares of Bruker by 13.6% during the second quarter. Marshall Wace North America L.P. now owns 1,430,133 shares of the medical research company’s stock worth $41,474,000 after purchasing an additional 170,863 shares during the last quarter. 65.58% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://transcriptdaily.com/2017/11/29/bruker-brkr-sets-new-12-month-high-at-35-51.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with MarketBeat.com's FREE daily email newsletter.